Soligenix, Inc. (NASDAQ: SNGX) shares slumped sharply Thursday. The Princeton, New Jersey-based Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the extended stability of ebolavirus vaccines using its ThermoVax® platform.
Bivalent and trivalent vaccines, constructed from antigens againstZaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus and the CoVaccine HT™ antigen, were formulated in a single vial and subjected to long-term storage at up to 40°C (104°F).
After two years of storage, all vaccines were unchanged and had equivalent potency as when initially manufactured. In collaboration with Axel Lehrer, PhD, Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawai?i at Manoa, the manuscript entitled "Thermostable Bivalent & Trivalent Filovirus Vaccines from Insect Cells: Potency Demonstrated after 3 Months and 2 Years", has been accepted for publication and is available online in Vaccine.
"Our filovirus vaccines have demonstrated broad and robust immune responses in mice and up to 100% protection in non-human primates," stated Dr. Lehrer. "This further demonstration of extended stability is particularly relevant for the use of these vaccines in virus-endemic countries in Africa, as well as in the context of strategic national stockpiles and preparations for potential larger outbreaks and pandemics.”
SNGX shares plunged 34 cents, or 11%, to $2.74.
